Some Respond to Nivolumab After Melanoma Progression (CME/CE)

(MedPage Today) -- Tumors shrank in 28% of those who stayed on drug after disease progression

Source: MedPage Today State Required CME - July 1, 2017 Category: Consumer Health News Source Type: news